| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation to the consolidated net loss for the six months ended June 30, 2026, and 2025 is included at the bottom of the table below.
| | | Three Months Ended
June 30, | | | Six Months Ended
June 30, | |
| Significant segment expenses | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| General and administrative (1) | | | 1,584,064 | | | | 1,460,723 | | | | 3,224,150 | | | | 3,157,148 | |
| Pre-clinical research (1) | | | 57,436 | | | | 103,343 | | | | 431,797 | | | | 165,336 | |
| Non-clinical research (1) | | | 401,266 | | | | - | | | | 401,266 | | | | | |
| CMC (1) | | | 955,875 | | | | 99,413 | | | | 1,614,273 | | | | 324,010 | |
| Clinical development (1) | | | 2,227,156 | | | | 1,928,275 | | | | 4,134,232 | | | | 3,363,079 | |
| Depreciation and amortization | | | 157,541 | | | | 161,746 | | | | 315,082 | | | | 323,454 | |
| Share based compensation expense | | | 329,944 | | | | 57,645 | | | | 469,126 | | | | 156,203 | |
| Other segment items (2) | | | - | | | | (246 | ) | | | - | | | | 1,848 | |
| Total operating and segment expenses | | | 5,713,282 | | | | 3,810,899 | | | | 10,589,926 | | | | 7,491,078 | |
| | | | | | | | | | | | | | | | | |
| Reconciliation of net loss | | | | | | | | | | | | | | | | |
| Change in fair value of warrant liabilities | | | 20,624 | | | | (8,436 | ) | | | 1,562,756 | | | | 68,431 | |
| Realized foreign currency translation loss from dissolution of subsidiaries | | | - | | | | - | | | | - | | | | (7,171 | ) |
| Foreign currency gain/(loss) | | | (29,792 | ) | | | 29,290 | | | | (39,283 | ) | | | 29,290 | |
| Other income | | | 38,182 | | | | 19,464 | | | | 62,365 | | | | 19,464 | |
| Interest and dividends, net | | | 410,416 | | | | 54,424 | | | | 860,754 | | | | 101,669 | |
| Segment and consolidated net loss | | | 5,273,852 | | | | 3,716,157 | | | | 8,143,334 | | | | 7,279,395 | |
| (1) | includes personnel costs and excludes share-based compensation expense and impairment expense |
| | |
| (2) | includes litigation settlements, loss from sale of assets, and loss on asset write offs |
|